摘要:
7-Acylamino-3-pyrazinylthiomethyl-3-cephem-4-carboxylic acids are disclosed having the general formula: ##STR1## wherein R is an alkyl having from 1 to 5 carbon atoms or ##STR2## wherein Y = Y.sup.1 = HY = y.sup.1 = clY = cl, Y.sup.1 = FY = h,y .sup.1 = cl andIn which n is an integer from 1 to 4, X is O or S, and R.sub.2 is thienyl, phenyl, 1,4-cyclohexadienyl, phenoxy, pyrazinyl and substituted phenyl, thienyl, pyrazinyl and phenoxy, the substituent being selected from the group consisting of hydroxy, chlorine, bromine, and alkyl and alkoxy having from 1 to 4 carbon atoms;R.sub.3 is alkali metal such as sodium or potassium, hydrogen, alkyl having from 1 to 4 carbon atoms, benzyl, trichloroethyl, methoxybenzyl, benzhydryl, pivaloyloxymethyl, and an alkaline earth metal; R.sup.1 may be a pyrazinyl of the general formulae: ##STR3## in which R.sup.4, R.sup.5, R.sup.6 are equal or different and are selected from the group consisting of F, Cl, Br, hydrogen, alkyl, phenyl, cyano, thiocyano, carboxyl, carboxyalkyl, carboxamido, thiocarboxamido, hydroxy, alkoxy, thiol, alkylthio, amino, alkylamino, phenylamino. By the terms alkyl, an alkyl having from 1 to 4 carbon atoms is intended. Processes for making them are also disclosed.The new cephalosporin derivatives of formula (I) exhibit a broad spectrum antibacterial activity and are useful as therapeutic agents in the treatment of infectious diseases caused by gram-negative and gram-positive bacteria.
摘要翻译:公开了具有以下通式的7-酰基氨基-3-吡嗪基硫甲基-3-头孢烯-4-羧酸:其中R是具有1至5个碳原子的烷基或者具有1或5个碳原子的烷基 其中Y = Y1 = HY = Y1 = C1 Y = C1,Y1 = FY = H,Y1 = C1和IN,其中N为1至4的整数,X为O或S,R2为噻吩基, 苯基,1,4-环己二烯基,苯氧基,吡嗪基和取代的苯基,噻吩基,吡嗪基和苯氧基,所述取代基选自羟基,氯,溴以及具有1至4个碳原子的烷基和烷氧基; R3是碱金属如钠或钾,氢,具有1至4个碳原子的烷基,苄基,三氯乙基,甲氧基苄基,二苯甲基,新戊酰氧基甲基和碱土金属; R 1可以是以下通式的吡嗪基:其中R 4,R 5,R 6相同或不同,并且选自F,Cl,Br,氢,烷基,苯基,氰基,硫氰基,羧基, 羧基烷基,甲酰氨基,硫代甲酰胺基,羟基,烷氧基,硫醇,烷硫基,氨基,烷基氨基,苯基氨基。 术语烷基是指具有1至4个碳原子的烷基。 还披露了制作它们的过程。
摘要:
Erythromycin 9-oxime derivatives wherein a phenyl or heterocylic group is attached indirectly to the 9-position of erythromycin A through an alkylene diamine bridging member. These compounds exhibit broad spectrum antibiotic activity.
摘要:
The present invention discloses an erythromycin derivative with antibiotic activity and pharmaceutically acceptable salts thereof, a process for their preparation and pharmaceutical compositions containing them as active principle.
摘要:
Compounds of formula ##STR1## wherein R.sub.1 is chloro, fluoro, bromo or trifluoromethyl;R.sub.2 is hydrogen, chloro , fluoro, bromo or trifluoromethyl;Z is CH or N;R.sub.3, R.sub.4 and R.sub.5, which are the same or different, are hydrogen or C.sub.1 -C.sub.4 alkyl, with the proviso that R.sub.4 is different from R.sub.5 when R.sub.3 is hydrogen;X is O, S, SO or SO.sub.2 ;R.sub.6 is a C.sub.1 -C.sub.5 polyfluoroalkyl group containing at least two fluorine atoms and optionally other halogen atoms selected from the group consisting of chloro and bromo; processes for their preparation and pharmaceutical compositions containing them are described.The compounds of formula II-A are endowed with a marked wide range antimycotic acitivity.
摘要:
Compounds of formula (I) wherein Ra and Rb the same or different, are hydrogen atoms, acyl groups deriving from a lower carboxylic acid or chains of formula (a) useful as reverse transcriptase inhibitors antiviral activity are described.
摘要:
Compounds of formula ##STR1## wherein R.sub.1 is chloro, fluoro, bromo or trifluoromethyl;R.sub.2 is hydrogen, chloro, fluoro, bromo or trifluoromethyl;Z is CH or N;R.sub.3, R.sub.4 and R.sub.5, which are the same or different, are hydrogen or C.sub.1 -C.sub.4 alkyl, with the proviso that R.sub.4 is different from R.sub.5 when R.sub.3 is hydrogen;X is O, S, SO or S0.sub.2 ;R.sub.6 is a C.sub.1 -C.sub.5 polyfluoroalkyl group containing at least two fluorine atoms and optionally other halogen atoms selected from the group consisting of chloro and bromo; processes for their preparation and pharmaceutical compositions containing them are described.The compounds of formula II-A are endowed with a marked wide range antimycotic acitivity.